<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9252932</PMID>
      <DateCompleted>
        <Year>1997</Year>
        <Month>09</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0024-7758</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>42</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>1997</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of reproductive medicine</Title>
          <ISOAbbreviation>J Reprod Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.</ArticleTitle>
        <Pagination>
          <StartPage>413</StartPage>
          <EndPage>423</EndPage>
          <MedlinePgn>413-23</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare intranasal nafarelin and intramuscular leuprolide acetate (LA) depot in the management of endometriosis.</AbstractText>
          <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range. For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily. Subjects were followed throughout treatment and for six months after treatment. The main outcome measures were changes in endometriosis symptoms and signs, BMD measurements, subject-reported and objectively measured hot flushes and circulating estradiol concentrations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Nafarelin was as effective as LA depot in alleviating symptoms and signs of endometriosis. LA depot recipients lost significantly more BMD, had more days with subjective hot flushes and more objectively measured hot flushes than did nafarelin recipients. In the nafarelin group, estradiol levels were consistently higher than in the leuprolide depot group, with significant differences by month 3 of dosing.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nafarelin and LA depot were equally effective despite higher estradiol levels in nafarelin recipients. Nafarelin-treated subjects lost less BMD, had fewer days with hot flushes and had fewer objectively measured hot flushes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Agarwal</LastName>
            <ForeName>S K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Cedara-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamrang</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henzl</LastName>
            <ForeName>M R</ForeName>
            <Initials>MR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Judd</LastName>
            <ForeName>H L</ForeName>
            <Initials>HL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Reprod Med</MedlineTA>
        <NlmUniqueID>0173343</NlmUniqueID>
        <ISSNLinking>0024-7758</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4TI98Z838E</RegistryNumber>
          <NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EFY6W0M8TG</RegistryNumber>
          <NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015519" MajorTopicYN="Y">Bone Density</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014666" MajorTopicYN="Y">Vasomotor System</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1997</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1997</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1997</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9252932</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
